REGENXBIO Inc. (RGNX) Stock Price
RGNXStock
$6.92−43.88%52W
Market Cap$457.14M
P/E—
PEG Ratio—
Div yield—
Beta1.21
RGNX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-35.44%
Price vs S&P 500 (4W)-10.79%
VGM Score52.38
RGNX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.11 | $0.43 | +499.22%(+$0.54) | |
| Q1 2026 | -$1.41 | -$1.72 | -21.64%(-$0.31) | |
| Q4 2025 | -$0.84 | -$1.30 | -54.92%(-$0.46) | |
| Q3 2025 | -$1.30 | -$1.20 | +7.57%(+$0.10) | |
| Q2 2025 | -$1.05 | -$1.38 | -30.83%(-$0.33) |
RGNX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.21
4.21
4.21
4.16
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RGNXREGENXBIO Inc. | C | B | D | 2.6x | 12.0% | 86.4% | — | $6.92 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About REGENXBIO Inc.
Regenxbio is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform based on adeno-associated virus (AAV) vectors. The company targets retinal, neuromuscular, and neurodegenerative diseases by delivering genes to cells to correct genetic defects or enable therapeutic protein production. Its pipeline addresses unmet medical needs in genetic and degenerative disorders.